Mind Medicine (MNMD) has released an update.
Mind Medicine Inc. has revealed new research at the ISPOR 2024 conference, showcasing the significant economic and societal costs associated with Generalized Anxiety Disorder (GAD) in the U.S. The company’s studies indicate that healthcare costs and work productivity are negatively impacted by GAD, particularly when it remains undiagnosed. Mind Medicine is committed to addressing these issues by developing new treatments for GAD and other brain health disorders.
For further insights into MNMD stock, check out TipRanks’ Stock Analysis page.
